Trademark: 79233134
Word
IMPLAVAX
Status
Registered
Status Code
700
Status Date
Tuesday, March 26, 2019
Serial Number
79233134
Registration Number
5706102
Registration Date
Tuesday, March 26, 2019
Mark Type
4000
Filing Date
Tuesday, March 20, 2018
Published for Opposition
Tuesday, January 8, 2019

Trademark Owner History
Enesi Pharma Limited - Original Registrant

Classifications
5 Pharmaceutical and veterinary preparations and substances for the treatment of and protection against infectious and autoimmune diseases; pharmaceutical and veterinary preparations and substances for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders; prophylactic pharmaceutical and veterinary preparations and substances against infectious and autoimmune diseases; vaccines, prophylactic vaccines, therapeutic vaccines; contraceptive preparations and substances
10 Surgical, medical, dental and veterinary apparatus and instruments, namely, drug delivery systems for delivery of drugs and vaccines; needle-free drug delivery systems sold empty; actuator devices, namely, medical solid dose injectors sold empty for injecting pharmaceutical and veterinary preparations into the skin; drug cassettes in the nature of drug and vaccine delivery systems sold empty; medical needle-free injection systems, needle-free injectors, namely, injection devices for administering drugs and vaccines sold empty; drug delivery injection devices for administering drugs and vaccines, namely, medical injectors, needle-free injectors and structural parts therefor sold empty; actuator devices for use in drug delivery devices, namely, handheld spring-powered devices in the nature of needle-free injection systems for injecting pharmaceutical and veterinary preparations into the skin sold empty; drug cassettes for use in drug delivery devices in the nature of drug and vaccine delivery systems sold empty to contain pharmaceutical preparations and substances for therapeutic, prophylactic and diagnostic use; replacement parts for all the aforesaid goods
Issue New Certificate to: "Enesi Pharma Limited (Great Britian Limited UK Company), 120 A&B Olympic Avenue, Milton Park, Abingdon, Oxfordshire OX144SA"

Trademark Events
Mar 26, 2024
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Jun 4, 2020
Counterclaim Opp. No. 999999
Jan 3, 2020
New Certificate Under Section 7 - Processed
Dec 9, 2019
Case Assigned To Post Registration Paralegal
Nov 5, 2019
Teas Section 7 Request Received
Oct 3, 2019
Change Of Name/Address Rec'd From Ib
Aug 16, 2019
Final Decision Transaction Processed By Ib
Jul 30, 2019
Final Disposition Notice Sent To Ib
Jul 30, 2019
Final Disposition Processed
Jun 26, 2019
Final Disposition Notice Created, To Be Sent To Ib
Mar 26, 2019
Registered-Principal Register
Jan 8, 2019
Official Gazette Publication Confirmation E-Mailed
Jan 8, 2019
Published For Opposition
Dec 19, 2018
Notification Of Notice Of Publication E-Mailed
Nov 14, 2018
Approved For Pub - Principal Register
Nov 1, 2018
Teas/Email Correspondence Entered
Oct 31, 2018
Correspondence Received In Law Office
Oct 31, 2018
Teas Request For Reconsideration Received
Oct 3, 2018
Notification Of Final Refusal Emailed
Oct 3, 2018
Final Refusal E-Mailed
Oct 3, 2018
Final Refusal Written
Sep 25, 2018
Teas/Email Correspondence Entered
Sep 25, 2018
Correspondence Received In Law Office
Sep 25, 2018
Teas Response To Office Action Received
Jul 27, 2018
Refusal Processed By Ib
Jul 12, 2018
Non-Final Action Mailed - Refusal Sent To Ib
Jul 12, 2018
Refusal Processed By Mpu
Jul 3, 2018
Non-Final Action (Ib Refusal) Prepared For Review
Jul 2, 2018
Non-Final Action Written
Jun 29, 2018
Assigned To Examiner
Jun 12, 2018
Application Filing Receipt Mailed
Jun 7, 2018
New Application Office Supplied Data Entered
May 31, 2018
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24